JP2014532626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532626A5 JP2014532626A5 JP2014537274A JP2014537274A JP2014532626A5 JP 2014532626 A5 JP2014532626 A5 JP 2014532626A5 JP 2014537274 A JP2014537274 A JP 2014537274A JP 2014537274 A JP2014537274 A JP 2014537274A JP 2014532626 A5 JP2014532626 A5 JP 2014532626A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- trifluoromethyl
- imidazo
- hydrogen
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 236
- 239000001257 hydrogen Substances 0.000 claims description 236
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 142
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 140
- -1 difluoromethoxy, trifluoromethoxy, oxazolyl Chemical group 0.000 claims description 139
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 110
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 104
- 150000002431 hydrogen Chemical class 0.000 claims description 96
- 150000002825 nitriles Chemical class 0.000 claims description 96
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 94
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 82
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 80
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 72
- 125000001246 bromo group Chemical group Br* 0.000 claims description 68
- 125000001153 fluoro group Chemical group F* 0.000 claims description 68
- 229910052757 nitrogen Inorganic materials 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 58
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 57
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 52
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 52
- 125000005475 oxolanyl group Chemical group 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 125000002757 morpholinyl group Chemical group 0.000 claims description 45
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims description 44
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 44
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 36
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 125000003386 piperidinyl group Chemical group 0.000 claims description 34
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 34
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 31
- 125000002541 furyl group Chemical group 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 125000002883 imidazolyl group Chemical group 0.000 claims description 28
- 125000004076 pyridyl group Chemical group 0.000 claims description 28
- 230000009385 viral infection Effects 0.000 claims description 28
- 208000036142 Viral infection Diseases 0.000 claims description 27
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 27
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 27
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 26
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000001544 thienyl group Chemical group 0.000 claims description 24
- 201000010153 skin papilloma Diseases 0.000 claims description 21
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 229940124530 sulfonamide Drugs 0.000 claims description 16
- 150000003456 sulfonamides Chemical class 0.000 claims description 16
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 16
- 208000000260 Warts Diseases 0.000 claims description 15
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 14
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 14
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 14
- 125000002971 oxazolyl group Chemical group 0.000 claims description 13
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 150000003457 sulfones Chemical class 0.000 claims description 12
- 150000003462 sulfoxides Chemical class 0.000 claims description 12
- 241000701806 Human papillomavirus Species 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 9
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims description 8
- YDVJBLJCSLVMSY-UHFFFAOYSA-N carbamoyl cyanide Chemical compound NC(=O)C#N YDVJBLJCSLVMSY-UHFFFAOYSA-N 0.000 claims description 8
- 210000004400 mucous membrane Anatomy 0.000 claims description 8
- RXFCBIOFXJLRDT-UHFFFAOYSA-N 2-[2-cyclopentyl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2CCCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 RXFCBIOFXJLRDT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 5
- NXWFZLSDGBWCMN-UHFFFAOYSA-N 1,3-oxazol-4-amine Chemical compound NC1=COC=N1 NXWFZLSDGBWCMN-UHFFFAOYSA-N 0.000 claims description 4
- UEEBKQWDBWDPKD-UHFFFAOYSA-N 1,3-oxazole-4-carbonitrile Chemical compound N#CC1=COC=N1 UEEBKQWDBWDPKD-UHFFFAOYSA-N 0.000 claims description 4
- NVZFORKBKKRTPC-UHFFFAOYSA-N 1-[2-(1,3,4-oxadiazol-2-yl)-6,8-bis(trifluoromethyl)pyrrolo[3,2-h]quinolin-1-yl]ethanone Chemical compound C=1C2=CC=C3C(C(F)(F)F)=CC(C(F)(F)F)=NC3=C2N(C(=O)C)C=1C1=NN=CO1 NVZFORKBKKRTPC-UHFFFAOYSA-N 0.000 claims description 4
- AARLOGDETIISCE-UHFFFAOYSA-N 1-cyano-N-ethoxy-N-propan-2-yloxyformamide Chemical compound CCON(OC(C)C)C(=O)C#N AARLOGDETIISCE-UHFFFAOYSA-N 0.000 claims description 4
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 claims description 4
- PWIDBQONFRLSHB-UHFFFAOYSA-N 2-(2,4-dimethylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C)=CC(C)=C3C=CC2=NC=1C1=NN=CO1 PWIDBQONFRLSHB-UHFFFAOYSA-N 0.000 claims description 4
- OVDQMFOFJGKNQJ-UHFFFAOYSA-N 2-(4-chloro-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(C)C)=CC(Cl)=C3C=CC2=NC=1C1=NN=CO1 OVDQMFOFJGKNQJ-UHFFFAOYSA-N 0.000 claims description 4
- SXJCXTRJWBFKTG-UHFFFAOYSA-N 2-(4-phenyl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1=CC=CC=C1 SXJCXTRJWBFKTG-UHFFFAOYSA-N 0.000 claims description 4
- GKAUJNGBWGBWPN-UHFFFAOYSA-N 2-[1-benzyl-6,8-bis(trifluoromethyl)pyrrolo[3,2-h]quinolin-2-yl]-1,3,4-oxadiazole Chemical compound C=1C=CC=CC=1CN1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=NN=CO1 GKAUJNGBWGBWPN-UHFFFAOYSA-N 0.000 claims description 4
- FYDPIVQTBUDNFZ-UHFFFAOYSA-N 2-[1-methyl-6,8-bis(trifluoromethyl)pyrrolo[3,2-h]quinolin-2-yl]-1,3,4-oxadiazole Chemical compound C=1C2=CC=C3C(C(F)(F)F)=CC(C(F)(F)F)=NC3=C2N(C)C=1C1=NN=CO1 FYDPIVQTBUDNFZ-UHFFFAOYSA-N 0.000 claims description 4
- GRHYZVJEXKTJOS-UHFFFAOYSA-N 2-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 GRHYZVJEXKTJOS-UHFFFAOYSA-N 0.000 claims description 4
- QWVRUQREZXNEJA-UHFFFAOYSA-N 2-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazole Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NC=CO1 QWVRUQREZXNEJA-UHFFFAOYSA-N 0.000 claims description 4
- FMTRHOIWPWHRKP-UHFFFAOYSA-N 2-[2,4-di(propan-2-yl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(C)C)=CC(C(C)C)=C3C=CC2=NC=1C1=NN=CO1 FMTRHOIWPWHRKP-UHFFFAOYSA-N 0.000 claims description 4
- OZSBUQCOVZFGGH-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(OC(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 OZSBUQCOVZFGGH-UHFFFAOYSA-N 0.000 claims description 4
- QBUBXOFXOWEBHR-UHFFFAOYSA-N 2-[2-(furan-3-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2=COC=C2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 QBUBXOFXOWEBHR-UHFFFAOYSA-N 0.000 claims description 4
- XSRCLMHZKWWMMN-UHFFFAOYSA-N 2-[2-chloro-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(Cl)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 XSRCLMHZKWWMMN-UHFFFAOYSA-N 0.000 claims description 4
- FAYSDPVMSHSKCO-UHFFFAOYSA-N 2-[2-cyclopropyl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2CC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 FAYSDPVMSHSKCO-UHFFFAOYSA-N 0.000 claims description 4
- YVDRGFKZVNBSHE-UHFFFAOYSA-N 2-[2-ethoxy-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(OCC)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 YVDRGFKZVNBSHE-UHFFFAOYSA-N 0.000 claims description 4
- KNEJRARJYGTLGH-UHFFFAOYSA-N 2-[2-ethyl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(CC)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 KNEJRARJYGTLGH-UHFFFAOYSA-N 0.000 claims description 4
- MLTVDJZRACHHIX-UHFFFAOYSA-N 2-[2-methyl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 MLTVDJZRACHHIX-UHFFFAOYSA-N 0.000 claims description 4
- BNWCHNKOUUUCMU-UHFFFAOYSA-N 2-[2-phenyl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C=2C=CC=CC=2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 BNWCHNKOUUUCMU-UHFFFAOYSA-N 0.000 claims description 4
- PKUZIWSJMAJAFL-UHFFFAOYSA-N 2-[2-propan-2-yl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(C)C)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 PKUZIWSJMAJAFL-UHFFFAOYSA-N 0.000 claims description 4
- PZOGDYJGGWPWII-UHFFFAOYSA-N 2-[2-pyridin-3-yl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C=2C=NC=CC=2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 PZOGDYJGGWPWII-UHFFFAOYSA-N 0.000 claims description 4
- RXORGTVUKXHNKO-UHFFFAOYSA-N 2-[2-thiophen-3-yl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2=CSC=C2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 RXORGTVUKXHNKO-UHFFFAOYSA-N 0.000 claims description 4
- LKUWFBQVSIRPML-UHFFFAOYSA-N 2-[6,8-bis(trifluoromethyl)imidazo[1,2-a]quinolin-2-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 LKUWFBQVSIRPML-UHFFFAOYSA-N 0.000 claims description 4
- ODUJRHUJULQYER-UHFFFAOYSA-N 2-[9-chloro-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound ClC=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 ODUJRHUJULQYER-UHFFFAOYSA-N 0.000 claims description 4
- DJEMXTIXIBTHNG-UHFFFAOYSA-N 2-[9-methyl-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound N1=C2C=CC3=C(C(F)(F)F)C=C(C(F)(F)F)N=C3N2C(C)=C1C1=NN=CO1 DJEMXTIXIBTHNG-UHFFFAOYSA-N 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- CQRMHSRHWONGKT-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazole Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=CN=CO1 CQRMHSRHWONGKT-UHFFFAOYSA-N 0.000 claims description 4
- MYAVWTCDDATPRC-UHFFFAOYSA-N 5-[6,8-bis(trifluoromethyl)-3h-imidazo[4,5-h]quinolin-2-yl]-1,3-oxazole Chemical compound N=1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2NC=1C1=CN=CO1 MYAVWTCDDATPRC-UHFFFAOYSA-N 0.000 claims description 4
- MPTASBRELSDHLR-UHFFFAOYSA-N 8-(furan-2-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=CC=CO1 MPTASBRELSDHLR-UHFFFAOYSA-N 0.000 claims description 4
- XLHJXZQVTKBZGE-UHFFFAOYSA-N C=1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2NC=1C1=NN=CO1 Chemical compound C=1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2NC=1C1=NN=CO1 XLHJXZQVTKBZGE-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- IYKWLKMNKIDWIV-UHFFFAOYSA-N N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=NN=CO1 Chemical compound N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=NN=CO1 IYKWLKMNKIDWIV-UHFFFAOYSA-N 0.000 claims description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- OIKZFUOILGIONH-UHFFFAOYSA-N cyclobutyl-[2-(1,3,4-oxadiazol-2-yl)-6,8-bis(trifluoromethyl)pyrrolo[3,2-h]quinolin-1-yl]methanone Chemical compound C1CCC1C(=O)N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=NN=CO1 OIKZFUOILGIONH-UHFFFAOYSA-N 0.000 claims description 4
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 4
- SKQVDXYIOKNAMW-UHFFFAOYSA-N difluoromethyl hypochlorite Chemical compound FC(F)OCl SKQVDXYIOKNAMW-UHFFFAOYSA-N 0.000 claims description 4
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 4
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- WELMECWTULNKJJ-ZDUSSCGKSA-N (5r)-5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-4,4-dimethyl-5h-1,3-oxazole Chemical compound CC1(C)N=CO[C@H]1C1=CN2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=N1 WELMECWTULNKJJ-ZDUSSCGKSA-N 0.000 claims description 2
- VVDNEMLZPLYFGY-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-n,n-dimethylmethanamine Chemical compound C1=C(C(F)(F)F)N=C2N3C=C(CN(C)C)N=C3C=CC2=C1C(F)(F)F VVDNEMLZPLYFGY-UHFFFAOYSA-N 0.000 claims description 2
- KOOHOBDNKYBBQD-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]imidazolidin-2-one Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1N1CCNC1=O KOOHOBDNKYBBQD-UHFFFAOYSA-N 0.000 claims description 2
- MTYSBJGTTWLOPD-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]imidazolidine-2,4-dione Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1N1CC(=O)NC1=O MTYSBJGTTWLOPD-UHFFFAOYSA-N 0.000 claims description 2
- FIOBXXPCLYHYPJ-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]pyrrolidin-2-one Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1N1CCCC1=O FIOBXXPCLYHYPJ-UHFFFAOYSA-N 0.000 claims description 2
- SBNVAZIJIYAPPW-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-yl)-6,8-bis(trifluoromethyl)-[1,3]oxazolo[5,4-h]quinoline Chemical compound N=1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2OC=1C1=NN=CO1 SBNVAZIJIYAPPW-UHFFFAOYSA-N 0.000 claims description 2
- BLISGSHAFWQYIT-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-yl)-6,8-bis(trifluoromethyl)furo[3,2-h]quinoline Chemical compound O1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=NN=CO1 BLISGSHAFWQYIT-UHFFFAOYSA-N 0.000 claims description 2
- LXVZWDSEPJDJNC-UHFFFAOYSA-N 2-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound C1N(C)CCC(C=2NC3=C4N=C(C=C(C4=CC=C3C=2)C(F)(F)F)C(F)(F)F)=C1 LXVZWDSEPJDJNC-UHFFFAOYSA-N 0.000 claims description 2
- XXERAWXJZUWPCD-UHFFFAOYSA-N 2-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound C1N(C)CCC=C1C1=CC2=CC=C(C(=CC(=N3)C(F)(F)F)C(F)(F)F)C3=C2N1 XXERAWXJZUWPCD-UHFFFAOYSA-N 0.000 claims description 2
- PFFUHRVXNYGXPB-UHFFFAOYSA-N 2-(1-methylpiperidin-3-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound C1N(C)CCCC1C1=CC2=CC=C(C(=CC(=N3)C(F)(F)F)C(F)(F)F)C3=C2N1 PFFUHRVXNYGXPB-UHFFFAOYSA-N 0.000 claims description 2
- JUXKERWCKMOTBT-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound C1CN(C)CCC1C1=CC2=CC=C(C(=CC(=N3)C(F)(F)F)C(F)(F)F)C3=C2N1 JUXKERWCKMOTBT-UHFFFAOYSA-N 0.000 claims description 2
- ILFFSXJKKNRCFD-UHFFFAOYSA-N 2-(2-propan-2-yl-4-propan-2-yloxyimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound CC(C)OC1=CC(C(C)C)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 ILFFSXJKKNRCFD-UHFFFAOYSA-N 0.000 claims description 2
- YEJBVDVPRNYIEH-UHFFFAOYSA-N 2-(2-propan-2-yl-4-pyrrolidin-1-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1N1CCCC1 YEJBVDVPRNYIEH-UHFFFAOYSA-N 0.000 claims description 2
- ZLQSJRQIGDOORQ-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=CCOCC1 ZLQSJRQIGDOORQ-UHFFFAOYSA-N 0.000 claims description 2
- YCQODIDSIDSIED-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-5-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1=CCCOC1 YCQODIDSIDSIED-UHFFFAOYSA-N 0.000 claims description 2
- UOQQNVBXXOBIPQ-UHFFFAOYSA-N 2-(4-cyclobutyl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CCC1 UOQQNVBXXOBIPQ-UHFFFAOYSA-N 0.000 claims description 2
- BLFHDVYASQMCCA-UHFFFAOYSA-N 2-(4-cyclohexyl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CCCCC1 BLFHDVYASQMCCA-UHFFFAOYSA-N 0.000 claims description 2
- KZLWXJQGUWCYHK-UHFFFAOYSA-N 2-(4-cyclopentyl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CCCC1 KZLWXJQGUWCYHK-UHFFFAOYSA-N 0.000 claims description 2
- KCVHGMULFNAICQ-UHFFFAOYSA-N 2-(4-cyclopropyl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CC1 KCVHGMULFNAICQ-UHFFFAOYSA-N 0.000 claims description 2
- USCFQYUJHYSCFO-UHFFFAOYSA-N 2-(4-ethoxy-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound CCOC1=CC(C(C)C)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 USCFQYUJHYSCFO-UHFFFAOYSA-N 0.000 claims description 2
- SSOQKFHRKJJXDO-UHFFFAOYSA-N 2-(4-piperidin-1-yl-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1N1CCCCC1 SSOQKFHRKJJXDO-UHFFFAOYSA-N 0.000 claims description 2
- LHQVQJUSAWIFQV-UHFFFAOYSA-N 2-(oxan-3-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1CCCOC1 LHQVQJUSAWIFQV-UHFFFAOYSA-N 0.000 claims description 2
- HBPAKCNLWDTLFC-UHFFFAOYSA-N 2-(oxan-4-yl)-6,8-bis(trifluoromethyl)-1h-pyrrolo[3,2-h]quinoline Chemical compound N1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2C=C1C1CCOCC1 HBPAKCNLWDTLFC-UHFFFAOYSA-N 0.000 claims description 2
- DKBNJASPFGEQCQ-UHFFFAOYSA-N 2-[2,3-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C=3N=C(C(F)(F)F)C(C(F)(F)F)=CC=3C=CC2=NC=1C1=NN=CO1 DKBNJASPFGEQCQ-UHFFFAOYSA-N 0.000 claims description 2
- YMJPQGKQIIDXKZ-UHFFFAOYSA-N 2-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,6]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound N=1C(C(F)(F)F)=CN(C2=C3)C=1C(C(F)(F)F)=CC2=CN=C3C1=NN=CO1 YMJPQGKQIIDXKZ-UHFFFAOYSA-N 0.000 claims description 2
- RMASRUOJYAIVDM-UHFFFAOYSA-N 2-[2-(1-methylpiperidin-3-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1N(C)CCCC1C1=CC(C(F)(F)F)=C(C=CC=2N3C=C(N=2)C=2OC=NN=2)C3=N1 RMASRUOJYAIVDM-UHFFFAOYSA-N 0.000 claims description 2
- SWNOJVZBGGBDAI-UHFFFAOYSA-N 2-[2-(1-methylpiperidin-4-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1CN(C)CCC1C1=CC(C(F)(F)F)=C(C=CC=2N3C=C(N=2)C=2OC=NN=2)C3=N1 SWNOJVZBGGBDAI-UHFFFAOYSA-N 0.000 claims description 2
- BHBZUIWGOSUDKX-UHFFFAOYSA-N 2-[2-(1-methylpyrrolidin-2-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound CN1CCCC1C1=CC(C(F)(F)F)=C(C=CC=2N3C=C(N=2)C=2OC=NN=2)C3=N1 BHBZUIWGOSUDKX-UHFFFAOYSA-N 0.000 claims description 2
- QWWIYKSPPJEZQO-UHFFFAOYSA-N 2-[2-(1-methylpyrrolidin-3-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1N(C)CCC1C1=CC(C(F)(F)F)=C(C=CC=2N3C=C(N=2)C=2OC=NN=2)C3=N1 QWWIYKSPPJEZQO-UHFFFAOYSA-N 0.000 claims description 2
- YJJOFTWRNIMHCB-UHFFFAOYSA-N 2-[2-(2-methylpropyl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(CC(C)C)=CC(C(F)(F)F)=C3C=CC2=NC=1C1=NN=CO1 YJJOFTWRNIMHCB-UHFFFAOYSA-N 0.000 claims description 2
- LUICBNKUMBSMTK-UHFFFAOYSA-N 2-[2-(cyclopentylmethyl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound N=1C(N2C=C(N=C2C=C2)C=3OC=NN=3)=C2C(C(F)(F)F)=CC=1CC1CCCC1 LUICBNKUMBSMTK-UHFFFAOYSA-N 0.000 claims description 2
- OGUNETWFMWRARH-UHFFFAOYSA-N 2-[2-(oxan-3-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2COCCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 OGUNETWFMWRARH-UHFFFAOYSA-N 0.000 claims description 2
- KEFLWXWDVGYNJN-UHFFFAOYSA-N 2-[2-(oxan-4-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2CCOCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 KEFLWXWDVGYNJN-UHFFFAOYSA-N 0.000 claims description 2
- HDVNOAPGOZANQJ-UHFFFAOYSA-N 2-[2-(oxolan-2-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2OCCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 HDVNOAPGOZANQJ-UHFFFAOYSA-N 0.000 claims description 2
- MCXJNRGGSYHSJD-UHFFFAOYSA-N 2-[2-(oxolan-3-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C1=CC(C2COCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 MCXJNRGGSYHSJD-UHFFFAOYSA-N 0.000 claims description 2
- DROZWOBCZYDKIM-UHFFFAOYSA-N 2-[2-propan-2-yl-3-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1=C(C(F)(F)F)C(C(C)C)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 DROZWOBCZYDKIM-UHFFFAOYSA-N 0.000 claims description 2
- QBOKHQJEJRLURL-UHFFFAOYSA-N 2-[3,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C=1C(C(F)(F)F)=CN=C(N2C=3)C=1C=CC2=NC=3C1=NN=CO1 QBOKHQJEJRLURL-UHFFFAOYSA-N 0.000 claims description 2
- MTZIHVKLVCEOQV-UHFFFAOYSA-N 2-[3-(1-methylpiperidin-4-yl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1CN(C)CCC1C1=CN=C2N3C=C(C=4OC=NN=4)N=C3C=CC2=C1 MTZIHVKLVCEOQV-UHFFFAOYSA-N 0.000 claims description 2
- UEIBLNWCBMUJML-UHFFFAOYSA-N 2-[3-(oxolan-3-yl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C1OCCC1C1=CN=C2N3C=C(C=4OC=NN=4)N=C3C=CC2=C1 UEIBLNWCBMUJML-UHFFFAOYSA-N 0.000 claims description 2
- QYTZWIWZNKPJEU-UHFFFAOYSA-N 2-[3-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1C(C(F)(F)F)=CN=C(N2C=3)C=1C=CC2=NC=3C1=NN=CO1 QYTZWIWZNKPJEU-UHFFFAOYSA-N 0.000 claims description 2
- HYXVOSRUQSBMLY-UHFFFAOYSA-N 2-[3-propan-2-yl-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound FC(F)(F)C=1C(C(C)C)=CN=C(N2C=3)C=1C=CC2=NC=3C1=NN=CO1 HYXVOSRUQSBMLY-UHFFFAOYSA-N 0.000 claims description 2
- KSJOQRCZTIYJTI-UHFFFAOYSA-N 2-[4-(1h-imidazol-2-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1=NC=CN1 KSJOQRCZTIYJTI-UHFFFAOYSA-N 0.000 claims description 2
- QINCCFVZMLWFJC-UHFFFAOYSA-N 2-[4-(1h-imidazol-5-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1=CN=CN1 QINCCFVZMLWFJC-UHFFFAOYSA-N 0.000 claims description 2
- SCIGHLYGHKOPOP-UHFFFAOYSA-N 2-[4-(2-methylpropyl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound CC(C)CC1=CC(C(C)C)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 SCIGHLYGHKOPOP-UHFFFAOYSA-N 0.000 claims description 2
- XUIWXKIMQCIUKJ-UHFFFAOYSA-N 2-[4-(oxolan-2-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CCCO1 XUIWXKIMQCIUKJ-UHFFFAOYSA-N 0.000 claims description 2
- FDRYFSUYPWYYFD-UHFFFAOYSA-N 2-[4-(oxolan-3-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C1CCOC1 FDRYFSUYPWYYFD-UHFFFAOYSA-N 0.000 claims description 2
- YULVOSDBWLYKHF-UHFFFAOYSA-N 2-[5-pyrrolidin-1-yl-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C(N3CCCC3)=CC2=NC=1C1=NN=CO1 YULVOSDBWLYKHF-UHFFFAOYSA-N 0.000 claims description 2
- NQKMAQAJAIKVHX-UHFFFAOYSA-N 2-[5-pyrrolidin-1-yl-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C=1N2C3=NC(C(F)(F)F)=CC=C3C(N3CCCC3)=CC2=NC=1C1=NN=CO1 NQKMAQAJAIKVHX-UHFFFAOYSA-N 0.000 claims description 2
- CQGGENGZMJDSOW-UHFFFAOYSA-N 2-[6,8-bis(trifluoromethyl)-[1,3]thiazolo[5,4-h]quinolin-2-yl]-1,3,4-oxadiazole Chemical compound N=1C=2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC=2SC=1C1=NN=CO1 CQGGENGZMJDSOW-UHFFFAOYSA-N 0.000 claims description 2
- WFEOFJMBPIGBKR-UHFFFAOYSA-N 2-[6-pyrrolidin-1-yl-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C12=NC(C=3OC=NN=3)=CN2C2=NC(C(F)(F)F)=CC(C(F)(F)F)=C2C=C1N1CCCC1 WFEOFJMBPIGBKR-UHFFFAOYSA-N 0.000 claims description 2
- UUHPZAQGKPYTOZ-UHFFFAOYSA-N 2-[6-pyrrolidin-1-yl-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole Chemical compound C12=NC(C=3OC=NN=3)=CN2C2=NC(C(F)(F)F)=CC=C2C=C1N1CCCC1 UUHPZAQGKPYTOZ-UHFFFAOYSA-N 0.000 claims description 2
- NTGKXXXYSATVND-UHFFFAOYSA-N 3-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazolidin-2-one Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1N1CCOC1=O NTGKXXXYSATVND-UHFFFAOYSA-N 0.000 claims description 2
- UXVLWGONDJLWNV-UHFFFAOYSA-N 4-[[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]methyl]morpholine Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1CN1CCOCC1 UXVLWGONDJLWNV-UHFFFAOYSA-N 0.000 claims description 2
- HXKHYBDMMRUWCD-UHFFFAOYSA-N 4-[[8-(1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-2-yl]methyl]morpholine Chemical compound N=1C(N2C=C(N=C2C=C2)C=3OC=NN=3)=C2C(C(F)(F)F)=CC=1CN1CCOCC1 HXKHYBDMMRUWCD-UHFFFAOYSA-N 0.000 claims description 2
- KYPOLJNXQFMSTH-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazol-4-amine Chemical compound N1=COC(C=2N=C3N(C4=NC(=CC(=C4C=C3)C(F)(F)F)C(F)(F)F)C=2)=C1N KYPOLJNXQFMSTH-UHFFFAOYSA-N 0.000 claims description 2
- IVMKXTHHQVTJQG-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazole-4-carbonitrile Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1C=1OC=NC=1C#N IVMKXTHHQVTJQG-UHFFFAOYSA-N 0.000 claims description 2
- UKCMJBXAZVFVDQ-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3-oxazole-4-carboxamide Chemical compound N1=COC(C=2N=C3N(C4=NC(=CC(=C4C=C3)C(F)(F)F)C(F)(F)F)C=2)=C1C(=O)N UKCMJBXAZVFVDQ-UHFFFAOYSA-N 0.000 claims description 2
- RZFXDEIOTUSFIM-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-4-methyl-1,3-oxazole Chemical compound N1=COC(C=2N=C3N(C4=NC(=CC(=C4C=C3)C(F)(F)F)C(F)(F)F)C=2)=C1C RZFXDEIOTUSFIM-UHFFFAOYSA-N 0.000 claims description 2
- GLIGDRAWLVTMFY-UHFFFAOYSA-N 5-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-4-propan-2-yl-1,3-oxazole Chemical compound N1=COC(C=2N=C3N(C4=NC(=CC(=C4C=C3)C(F)(F)F)C(F)(F)F)C=2)=C1C(C)C GLIGDRAWLVTMFY-UHFFFAOYSA-N 0.000 claims description 2
- CVDCVFQJFWRKHL-UHFFFAOYSA-N 8-(1,3,4-oxadiazol-2-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-5-carbonitrile Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C(C#N)=CC2=NC=1C1=NN=CO1 CVDCVFQJFWRKHL-UHFFFAOYSA-N 0.000 claims description 2
- UGZFGRFKWIFPCN-UHFFFAOYSA-N 8-(1,3,4-oxadiazol-2-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-6-carbonitrile Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=C(C#N)C2=NC=1C1=NN=CO1 UGZFGRFKWIFPCN-UHFFFAOYSA-N 0.000 claims description 2
- WDTBLQOMCKODCH-UHFFFAOYSA-N 8-(1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-5-carbonitrile Chemical compound C=1N2C3=NC(C(F)(F)F)=CC=C3C(C#N)=CC2=NC=1C1=NN=CO1 WDTBLQOMCKODCH-UHFFFAOYSA-N 0.000 claims description 2
- YQFFXFBLXQQTFU-UHFFFAOYSA-N 8-(1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-6-carbonitrile Chemical compound C=1N2C3=NC(C(F)(F)F)=CC=C3C=C(C#N)C2=NC=1C1=NN=CO1 YQFFXFBLXQQTFU-UHFFFAOYSA-N 0.000 claims description 2
- UKOVBQYOPDKNDM-UHFFFAOYSA-N 8-(1,3,4-oxadiazol-2-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridine-4-carbonitrile Chemical compound C=1N2C3=NC(C(C)C)=CC(C#N)=C3C=CC2=NC=1C1=NN=CO1 UKOVBQYOPDKNDM-UHFFFAOYSA-N 0.000 claims description 2
- OWOFSPFJFYJBEQ-UHFFFAOYSA-N 8-(pyrrolidin-1-ylmethyl)-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine Chemical compound C=1N2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=NC=1CN1CCCC1 OWOFSPFJFYJBEQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010059313 Anogenital warts Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- YGAPOBBJIFKGHV-UHFFFAOYSA-N N-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-5-carboxamide Chemical compound N1=CC=CC=2C(=CC=3N(C1=2)C=CN=3)C(=O)NC(F)(F)F YGAPOBBJIFKGHV-UHFFFAOYSA-N 0.000 claims description 2
- MKJIAYRKZYMSAG-UHFFFAOYSA-N N-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-6-carboxamide Chemical compound N1=CC=CC=2C=C(C=3N(C1=2)C=CN=3)C(=O)NC(F)(F)F MKJIAYRKZYMSAG-UHFFFAOYSA-N 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 2
- 201000004201 anogenital venereal wart Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 201000004196 common wart Diseases 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000008088 immune pathway Effects 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- AFROFFWOFNJJMA-UHFFFAOYSA-N morpholin-4-yl-[8-(1,3,4-oxadiazol-2-yl)-2-propan-2-ylimidazo[1,2-a][1,8]naphthyridin-4-yl]methanone Chemical compound C=12C=CC3=NC(C=4OC=NN=4)=CN3C2=NC(C(C)C)=CC=1C(=O)N1CCOCC1 AFROFFWOFNJJMA-UHFFFAOYSA-N 0.000 claims description 2
- QDOPWPLCBIVZQR-UHFFFAOYSA-N morpholin-4-yl-[8-(1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-2-yl]methanone Chemical compound FC(F)(F)C1=CC(C(=O)N2CCOCC2)=NC(N2C=3)=C1C=CC2=NC=3C1=NN=CO1 QDOPWPLCBIVZQR-UHFFFAOYSA-N 0.000 claims description 2
- 210000003899 penis Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims 2
- YVBPNYXAQNAMLH-UHFFFAOYSA-N 1-hydroxy-2-methylpyrrolidine Chemical compound CC1CCCN1O YVBPNYXAQNAMLH-UHFFFAOYSA-N 0.000 claims 1
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical compound C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 23
- 0 **CC(N1CCOCC1)=O Chemical compound **CC(N1CCOCC1)=O 0.000 description 14
- 125000001188 haloalkyl group Chemical group 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 4
- AESFASYGJMUOLW-UHFFFAOYSA-N N=COC(c(nc1cc2)c[n]1c1c2C(C(F)(F)F)=CC(C2CCCC2)=C=C1)=N Chemical compound N=COC(c(nc1cc2)c[n]1c1c2C(C(F)(F)F)=CC(C2CCCC2)=C=C1)=N AESFASYGJMUOLW-UHFFFAOYSA-N 0.000 description 2
- GLRRWFXFSXZSDZ-UHFFFAOYSA-M O=C(N1CCOCC1)[S-] Chemical compound O=C(N1CCOCC1)[S-] GLRRWFXFSXZSDZ-UHFFFAOYSA-M 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- WDUYIEVHJVPIIO-UHFFFAOYSA-N 1-[[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]methyl]pyrrolidin-3-ol Chemical compound C1C(O)CCN1CC1=CN2C3=NC(C(F)(F)F)=CC(C(F)(F)F)=C3C=CC2=N1 WDUYIEVHJVPIIO-UHFFFAOYSA-N 0.000 description 1
- DLEWDCPFCNLJEY-UHFFFAOYSA-N CCC(N1CCOCC1)=O Chemical compound CCC(N1CCOCC1)=O DLEWDCPFCNLJEY-UHFFFAOYSA-N 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 206010065173 Viral skin infection Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US61/549,784 | 2011-10-21 | ||
| US201261692431P | 2012-08-23 | 2012-08-23 | |
| US61/692,431 | 2012-08-23 | ||
| PCT/US2012/060971 WO2013059559A2 (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532626A JP2014532626A (ja) | 2014-12-08 |
| JP2014532626A5 true JP2014532626A5 (https=) | 2015-12-03 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537274A Pending JP2014532626A (ja) | 2011-10-21 | 2012-10-19 | 自然免疫応答を増強する化合物および方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (https=) |
| EP (1) | EP2768506A4 (https=) |
| JP (1) | JP2014532626A (https=) |
| KR (1) | KR20140094559A (https=) |
| CN (1) | CN103957910A (https=) |
| AR (1) | AR088793A1 (https=) |
| AU (1) | AU2012325971B2 (https=) |
| BR (1) | BR112014008727A2 (https=) |
| CA (1) | CA2851801A1 (https=) |
| CL (1) | CL2014001016A1 (https=) |
| CO (1) | CO6910198A2 (https=) |
| CR (1) | CR20140175A (https=) |
| DO (1) | DOP2014000081A (https=) |
| EA (1) | EA201490610A1 (https=) |
| IL (1) | IL231894A0 (https=) |
| MX (1) | MX2014004814A (https=) |
| PE (1) | PE20141359A1 (https=) |
| PH (1) | PH12014500865A1 (https=) |
| SG (2) | SG10201505664WA (https=) |
| TW (2) | TW201542567A (https=) |
| UY (1) | UY34406A (https=) |
| WO (1) | WO2013059559A2 (https=) |
| ZA (1) | ZA201402392B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| JP2017531631A (ja) | 2014-09-29 | 2017-10-26 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 伝染性軟属腫ウイルスに対する抗ウイルス薬 |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| CA3057741A1 (en) | 2017-03-28 | 2018-10-04 | Pimera, Inc. | Novel crystal forms of a pol1 inhibitor |
| JP7443357B2 (ja) | 2018-10-23 | 2024-03-05 | ビーエーエスエフ ソシエタス・ヨーロピア | 三環式の殺有害生物化合物 |
| CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
| US20230322779A1 (en) * | 2020-09-03 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| CN120916763A (zh) * | 2023-04-14 | 2025-11-07 | 人福医药美国公司 | 用于治疗疼痛和相关医学病症的单酰甘油脂肪酶（magl）抑制剂 |
| WO2025089372A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人理化学研究所 | イソインドリン誘導体 |
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59104A (en) * | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| EP1492790A1 (en) * | 2002-04-03 | 2005-01-05 | F. Hoffmann-La Roche Ag | Imidazo fused compounds |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| WO2010113416A1 (ja) * | 2009-03-31 | 2010-10-07 | ダイキン工業株式会社 | 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子 |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532626A5 (https=) | ||
| US9926285B2 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| JP6483610B2 (ja) | ５，５−ヘテロ芳香族抗感染症化合物 | |
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| JP7034162B2 (ja) | インフルエンザウイルス複製の阻害剤及びその使用 | |
| RU2012126083A (ru) | Производные аминооксазина | |
| RU2014101071A (ru) | КОМПЛЕКСНЫЕ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ ПИРИДОПИРИМИДИНОНОВЫХ ИНГИБИТОРОВ РI3К/mTOR С БЕНДАМУСТИНОМ И/ИЛИ РИТУКСИМАБОМ | |
| KR20190126102A (ko) | 시클릭 술파미드 화합물 및 그의 사용 방법 | |
| AU2007246172A1 (en) | Integrase inhibitors 3 | |
| JP2009528389A5 (https=) | ||
| JP2007512299A5 (https=) | ||
| JP2022025116A (ja) | 抗菌性化合物 | |
| BRPI0716407A2 (pt) | Compostos orgânicos | |
| WO2014057435A1 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
| AU2007256708A1 (en) | Organic compounds | |
| EP2909193A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| TW201333003A (zh) | 用於增進先天性免疫反應之化合物及方法 | |
| EP4514790A1 (en) | Compounds for inhibiting kif18a | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| WO2014017093A1 (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| JP2014520885A5 (https=) | ||
| WO2012085857A1 (en) | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides | |
| KR20200123846A (ko) | 신규한 아릴 또는 헤테로아릴 트리아졸론 유도체 또는 그의 염, 또는 그를 포함하는 제약 조성물 | |
| CA2762620A1 (en) | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | |
| RU2016101983A (ru) | Конденсированные пятичленные гетероциклические пиридиновые соединения, способ их производства и применение |